kwic
observed
observed
right
off
ON
304
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for observed out of >500 occurrences
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to observed]
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 304) No signs of ATL were observed and HTLV-1 markers, such as proviral load and clonality of HTLV-1-infected cells, showed no significant change in either of two cases. |
| PMID:24252020 DOI:10.3109/14397595.2013.844389 |
| 2015 Modern rheumatology |
| * Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series. |
| - Anti-tumor necrosis factor (anti-TNF) biologics are effective in the treatment of rheumatoid arthritis (RA); however, it is still not clear whether this treatment promotes the development of malignancies such as lymphoma. Human T-lymphotropic virus type 1 (HTLV-1), which is a causative agent of adult T-cell lymphoma (ATL), is prevalent in Japan. Many HTLV-1-positive patients with RA are assumed to exist; however, there have thus far been no reports on the effect of anti-TNF biologics on HTLV-1-positive patients. We analyzed the response to treatment with anti-TNF biologics and change of HTLV-1 markers in two cases of RA. The two cases showed no response based on the European League Against of Rheumatism response criteria 60-96 weeks after administration of anti-TNF biologics (infliximab and etanercept). No signs of ATL were observed and HTLV-1 markers, such as proviral load and clonality of HTLV-1-infected cells, showed no significant change in either of two cases. Therefore, treatment with anti-TNF biologics did not induce activation of HTLV-1, although the effect on RA was not as effective as in HTLV-1-negative patients in this limited study. Further long-term study with a greater number of patients is necessary to clarify the safety and efficacy of anti-TNF biologics in HTLV-1-positive patients with RA. |
[
right
kwic]
(1)155  in |
(9)9 on |
(17)4 a |
(25)2 data |
| (2)48 *null* | (10)8 by |
(18)4 during |
(26)2 experimentally |
| (3)36 that |
(11)8 to |
(19)4 the |
(27)2 reduction |
| (4)19 for |
(12)8 when |
(20)3 variation |
(28)2 significant |
| (5)18 at |
(13)6 among |
(21)2 as |
(29)2 through |
| (6)16 between |
(14)6 following |
(22)2 changes |
(30)2 throughout |
| (7)11 with |
(15)5 after |
(23)2 clinical |
(31)2 up |
| (8)9 and |
(16)5 from |
(24)2 compared |
(32)2 using |
add keyword
--- WordNet output for observed ---